NCE-1 Intelligence & Market Opportunity

Qfitlia

Fitusiran

Hemostatic Agents

Subcutaneous Solution

Qfitlia is a subcutaneous therapy approved for routine prevention of bleeding in patients aged 12 and older with hemophilia A or B, with or without inhibitors. It lowers antithrombin to rebalance clotting and has been shown to reduce annual bleeding rates by around 90%

Approval Date

28-Mar-25

NCE-1 Date

28-Mar-29

NCE Date

28-Mar-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

171.46%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

147

2027

292

2028

442

2029

543

2030

605

2031

689

2032

751

Molecule profile

Details & specifications

Molecule

Fitusiran

Innovator

GENZYME CORP

Dosage Form

Subcutaneous Solution

Strength

EQ 20 mg base/0.2 mL and EQ 50 mg base/0.5 mL

Therapeutic Category

Hemostatic Agents

Usage

To prevent or reduce the frequency of bleeding episodes in hemophilia a or B

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets